Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves' hyperthyroidism

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 4, 2016, Pages 1381-1389

  Vos, Xander G ^a   Endert, Erik ^a   Zwinderman, A H ^a   Tijssen, Jan G P ^a   Wiersinga, Wilmar M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; CYTOSINE; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; LEVOTHYROXINE; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; THIAMAZOLE; THYMINE; THYROXINE; AUTOANTIBODY;

ADULT; AGE; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; GRAVES DISEASE; HLA DQA1 GENE; HLA DQB1 GENE; HLA DRB1 GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PREDICTION; PROSPECTIVE STUDY; PTPN22 GENE; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE RISK; BLOOD; CLINICAL TRIAL; HYPERTHYROIDISM; MIDDLE AGED; PATHOPHYSIOLOGY; RECURRENT DISEASE; RISK FACTOR;

ADULT; ANTITHYROID AGENTS; AUTOANTIBODIES; FEMALE; GRAVES DISEASE; HUMANS; HYPERTHYROIDISM; MALE; METHIMAZOLE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; THYROXINE;

EID: 85011313838     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-3644     Document Type: Article

References (36)

1. Burch HB, Burman KD, Cooper DS. A 2011 Survey of Clinical Practice Patterns in the Management of Graves' Disease. J Clin Endocrinol Metab. 2012;97(12):4549-4558.
2. Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA. Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab. 2000;85(3):1038-1042.
3. Schleusener H, Schwander J, Fischer C, et al. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease. Acta Endocrinol (Copenh). 1989;120(6):689-701.
4. Vitti P, Rago T, Chiovato L, et al. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid. 1997;7(3):369-375.
5. Winsa B, Dahlberg A, Jansson R, Agren H, Karlsson FA. Factors influencing the outcome of thyrostatic drug therapy in Graves' disease. Acta Endocrinol (Copenh). 1990;122(6):722-728.
6. Yamada T, Aizawa T, Koizumi Y, Komiya I, Ichikawa K, Hashizume K. Age-related therapeutic response to antithyroid drug in patients with hyperthyroid Graves' disease. J Am Geriatr Soc. 1994;42(5):513-516.
7. Weetman AP, Ratanachaiyavong S, Middleton GW, et al. Prediction of outcome in Graves' disease after carbimazole treatment. Q J Med. 1986;59(228):409-419.
8. Young ET, Steel NR, Taylor JJ, et al. Prediction of remission after antithyroid drug treatment in Graves' disease. Q J Med. 1988;66(250):175-189.
9. de Bruin TW, Bolk JH, Bussemaker JK, et al. Graves' disease: Immunological and immunogenetic indicators of relapse. Br Med J (Clin Res Ed). 1988;296(6632):1292-1295.
10. McGregor AM, Smith BR, Hall R, Petersen MM, Miller M, Dewar PJ. Prediction of relapse in hyperthyroid Graves' disease. Lancet. 1980;1(8178):1101-1103.
11. Törring O, Tallstedt L, Wallin G, et al. Graves' hyperthyroidism: Treatment with antithyroid drugs, surgery, or radioiodine-A prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab. 1996;81(8):2986-2993.
12. Wang PW, Chen IY, Liu RT, Hsieh CJ, Hsi E, Juo SH. Cytotoxic T lymphocyte-associated molecule-4 gene polymorphism and hyperthyroid Graves' disease relapse after antithyroid drug withdrawal: A follow-up study. J Clin Endocrinol Metab. 2007;92(7):2513-2518.
13. Kimball LE, Kulinskaya E, Brown B, Johnston C, Farid NR. Does smoking increase relapse rates in Graves' disease? J Endocrinol Invest. 2002;25(2):152-157.
14. Nedrebo BG, Holm PI, Uhlving S, et al. Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease. Eur J Endocrinol. 2002;147(5):583-589.
15. Cooper DS. Treatment of Thyrotoxicosis. In:Werner SC, Ingbar SH, Braverman LE, Cooper DS, eds. Werner, Ingbar's the thyoid: A fundamental and clinical text. 10th ed. Philadelphia: Lippincott Williams, Wilkins; 2013, 492-516.
16. Badenhoop K, Donner H, Braun J, Siegmund T, Rau H, Usadel KH. Genetic markers in diagnosis and prediction of relapse in Graves' disease. Exp Clin Endocrinol Diabetes. 1996;104 Suppl 4:98-100.
17. Kim KW, Park YJ, Kim TY, Park dJ, Park KS, Cho BY. Susceptible alleles of the CD40 and CTLA-4 genes are not associated with the relapse after antithyroid withdrawal in Graves' disease. Thyroid. 2007;17(12):1229-1234.
18. Kimura H, Kato Y, Shimizu S, Takano K, Sato K. Association of polymorphism at position 49 in exon 1 of the cytotoxic T-lymphocyte-associated factor 4 gene with Graves' disease refractory to medical treatment, but not with amiodarone-associated thyroid dysfunction. Thyroid. 2009;19(9):975-981.
19. Tanrikulu S, Erbil Y, Ademoglu E, et al. The predictive value of CTLA-4 and Tg polymorphisms in the recurrence of Graves' disease after antithyroid withdrawal. Endocrine. 2006;30(3):377-381.
20. Wang PW, Chen IY, Juo SH, Hsi E, Liu RT, Hsieh CJ. Genotype and phenotype predictors of relapse of graves' disease after antithyroid drug withdrawal. Eur Thyroid J. 2013;1(4):251-258.
21. Vos XG, Smit N, Endert E, Tijssen JG, Wiersinga WM. Frequency and characteristics of TBII-seronegative patients in a population with untreated Graves' hyperthyroidism: A prospective study. Clin Endocrinol (Oxf). 2008;69(2):311-317.
22. Perez C, Scrimshaw NS, Munoz JA. Technique of endemic goitre surveys. Monogr Ser World Health Organ. 1960;44:369-383.
23. Ban Y, Concepcion ES, Villanueva R, Greenberg DA, Davies TF, Tomer Y. Analysis of immune regulatory genes in familial and sporadic Graves' disease. J Clin Endocrinol Metab. 2004;89(9):4562-4568.
24. Velaga MR, Wilson V, Jennings CE, et al. The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. J Clin Endocrinol Metab. 2004;89(11):5862-5865.
25. Vos XG, Endert E, Tijssen JG, Wiersinga WM. Genotypes in relation to phenotypic appearance and exposure to environmental factors in Graves' hyperthyroidism. Eur J Endocrinol. 2012;167(6):783-792.
26. Zhu XL, Du T, Li JH, et al. Association of HLA-DQB1 gene polymorphisms with outcomes of HBV infection in Chinese Han population. Swiss Med Wkly. 2007;137(7-8):114-120.
27. Pera C, Delfino L, Longo A, Pistillo MP, Ferrara GB. Novel associations among HLA-DQA1 and -DQB1 alleles, revealed by high-resolution sequence-based typing (SBT). Tissue Antigens. 2000;55(3):275-279.
28. Albis-Camps M, Blasczyk R. Fluorotyping of HLA-DRB by sequence-specific priming and fluorogenic probing. Tissue Antigens. 1999;53(3):301-307.
29. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56(2):337-344.
30. R Core Team. R: A language and environment for statistical computing. R Foundation for statistical Computing. Vienna, Austria, 2013.
31. Benker G, Reinwein D, Kahaly G, et al. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs. Clin Endocrinol (Oxf). 1998;49(4):451-457.
32. Kawai K, Tamai H, Matsubayashi S, et al. A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs. Clin Endocrinol (Oxf). 1995;43(5):551-556.
33. Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Colman P. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs. Thyroid. 1998;8(2):119-124.
34. Skorka A, Bednarczuk T, Bar-Andziak E, Nauman J, Ploski R. Lymphoid tyrosine phosphatase (PTPN22/LYP) variant and Graves' disease in a Polish population: Association and gene dose-dependent correlation with age of onset. Clin Endocrinol (Oxf). 2005;62(6):679-682.
35. Patel NN, Abraham P, Buscombe J, Vanderpump MP. The cost effectiveness of treatment modalities for thyrotoxicosis in a U.K. center. Thyroid. 2006;16(6):593-598.
36. Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab. 2001;86(8):3611-3617.